Antares Pharma Announces Notice of Allowance for Elestrin™ Patent by U.S. Patent & Trademark Office

Business Wire, Feb 7, 2007

EWING, N.J. -- Antares Pharma, Inc. (Amex: AIS) announced receipt of notice of allowance from the United States Patent & Trademark Office (USPTO) covering the formulation used in Elestrin[TM] (estradiol gel) which was co-invented by Antares and our licensee, BioSante. The USPTO has stated that it intends to grant patent protection which covers the proprietary formulation used in Elestrin. The patent is expected to expire in 2021.

Two doses of Elestrin, 0.87 grams per day and 1.7 grams per day, were approved by the FDA. Elestrin 0.87 grams per day is the lowest dose of estradiol approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe vasomotor symptoms in menopausal women. BioSante received FDA approval of Elestrin in December 2006 and licensed the product for marketing to Bradley Pharmaceuticals, Inc. Jack E. Stover, President & Chief Executive Officer of Antares Pharma stated, "We believe this patent protection will serve to strengthen the commercial value of Elestrin which is slated to be launched by Bradley in mid 2007."

About Antares Pharma

Antares Pharma is a specialized pharma product development company focused on developing patented drug delivery systems and injectable device engineering capabilities. Antares' current technology platforms include its ATD[TM] Advanced Transdermal Delivery system, and its related TecTix[TM] system for topical and transmucosal delivery, its Easy Tec[TM] oral fast-melt technology, and subcutaneous injection technology platforms including both Vibex[TM] disposable mini-needle injection device and Valeo[TM]/Vision[R] reusable needle-free injection devices. Antares Pharma is committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new pharmaceutical products and injectable devices. Overall, Antares' product pipeline, if approved, will address unmet medical needs by reducing side effect profiles, improving safety, increasing effectiveness, and improving patient compliance and convenience. Antares Pharma has corporate headquarters in Princeton Crossroads Corporate Center in Ewing, NJ, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Safe Harbor Statement

In addition to historical facts or statements or current conditions, this press release contains forward-looking statements within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995, including statements regarding the timing of product sales, market estimates and market potential. Forward-looking statements provide Antares' current expectation or forecasts of future events. Antares' results could differ materially from those reflected in these forward-looking statements due to decisions of regulatory authorities, Antares' ability to execute on its development plans and general financial, economic, regulatory and political conditions affecting the pharmaceutical industry generally. For a discussion of these and other risks and uncertainties that may effect the forward-looking statements, please see the risk factors in Antares' quarterly and annual reports filed with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Additional risk factors include the risk that Elestrin may not be successfully marketed. Antares undertakes no obligation to update publicly any forward-looking statement.